on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech: Preliminary Results 2024
Sartorius Stedim Biotech has published its preliminary results for 2024, showing sales of €2,780 million, representing growth of 0.6% at constant exchange rates. Current EBITDA is €779 million with a stable margin of 28%. Net profit reaches €175 million.
Despite a challenging environment, the company has achieved its financial targets. Moderate but profitable growth is anticipated for 2025, with a positive accentuation at the end of 2024. Order intake increased by 12.9% in the same period.
EMEA grew by 5.9% while the Americas recorded a decline of 6.7%. In Asia Pacific, revenue increased by 4%. Capital expenditures decreased to a ratio of 12.2% of revenue.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news